{"nctId":"NCT00936741","briefTitle":"An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome","startDateStruct":{"date":"2009-07"},"conditions":["Cushing's Syndrome"],"count":30,"armGroups":[{"label":"Mifepristone","type":"EXPERIMENTAL","interventionNames":["Drug: mifepristone"]}],"interventions":[{"name":"mifepristone","otherNames":["CORLUX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have completed the Week 24 visit and the 6-Week Follow-up visit of Corcept Study C-1073-400 (NCT00569582).\n* In the opinion of the Investigator, are expected to maintain clinical benefit from mifepristone.\n* Women of childbearing potential have a negative serum pregnancy test at Entry.\n* Women of childbearing potential must be willing to use non-hormonal, medically acceptable methods of contraception during the study.\n* Are able to provide written informed consent\n* Are able to return to the investigative site to complete the study evaluations outlined in the protocol.\n* Will not use systemic estrogens during the study.\n\nExclusion Criteria:\n\n* Have an acute or unstable medical problem, which could be aggravated by mifepristone treatment.\n* Are taking medications within 14 days of the Entry visit that a) have a large first pass metabolism that is largely mediated by CYP3A4 and which have a narrow therapeutic margin; and/or b) are strong CYP3A4 inhibitors.\n* Female patients of reproductive potential, who are pregnant or who are unable or unwilling to use medically acceptable, non-hormonal methods of contraception during the study.\n* Have received investigational treatment (drug, biological agent or device) other than CORLUX (mifepristone) within 30 days of Entry\n* Have a history of an allergic reaction or intolerance to CORLUX (mifepristone)\n* Have uncorrected hypokalemia (potassium level of \\<3.5 mEq/L) at Entry. Spironolactone or eplerenone is allowed to control hypokalemia.\n* Postmenopausal women with a history of endometrial hyperplasia with atypia or pathological features consistent with endometrial carcinoma.\n* Thickened endometrium on the Entry Visit transvaginal ultrasound that has not resolved after induction of menstrual bleeding with progesterone.\n* Uncontrolled, clinically significant hypothyroidism or hyperthyroidism.\n* Any woman with an intact uterus who has a hemorrhagic disorder or is being treated with an anticoagulant (e.g. warfarin, heparin).\n* Have renal failure as defined by a serum creatinine of ≥2.2 mg/dL.\n* Elevated total bilirubin \\>1.5 ULN, elevated ALT or AST ≥3X the upper limit of normal.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Subjects who received at least one dose of mifepristone were included in the safety analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"The Long-term Benefit of Mifepristone Treatment in Cushing's Syndrome as Measured by Changes in the Score on the Physician's Global Assessment of Disease Severity","description":"The mean Investigator's rating of the change in subject's signs and symptoms of Cushing's syndrome from Baseline (Entry into C1073-415) to Endpoint on the Physician's Global Assessment of Disease Severity was ranked on a 9-point scale (9 = much worse, 7 = worse, 5 = no change, 3 = better, 1 = much better). Higher scores indicate more severe illness. Scoring was done at all visits except the 6 Week Follow-up visit; the final visit result (Endpoint) is reported here.\n\nThe instruction was \"Rate the change in the subject's signs and symptoms of Cushing's from Baseline (1 = much better to 9 = much worse)\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.74"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":30},"commonTop":["Nausea","Blood potassium decreased","Fatique","Headache","Endometrial hypertrophy"]}}}